Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06305780
PHASE2

RECOVER-AUTONOMIC Platform Protocol

Sponsor: Kanecia Obie Zimmerman

View on ClinicalTrials.gov

Summary

This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating various interventions for use in the treatment of autonomic dysfunction symptoms, including cardiovascular complications and postural orthostatic tachycardia syndrome (POTS), in PASC participants. The interventions tested will include non-pharmacologic care and pharmacologic therapies with study drugs.

Official title: RECOVER-AUTONOMIC: A Platform Protocol for Evaluation of Interventions for Autonomic Dysfunction in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

381

Start Date

2024-03-11

Completion Date

2025-07-09

Last Updated

2026-08-03

Healthy Volunteers

No

Interventions

DRUG

IVIG + Coordinated Care

Participants will receive IVIG for a duration of 9 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with IVIG administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through a care coordinator.

DRUG

IVIG Placebo + Coordinated Care

Normal saline given intravenously will be the control (placebo) product. Blinding IV bag and tubing covers will be used for both IVIG and Placebo administration. Participants will receive IVIG placebo for a duration of 9 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with IVIG placebo administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through a care coordinator.

DRUG

Ivabradine + Coordinated Care

Participants will receive Ivabradine for a duration of 3 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with ivabradine administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through care coordinator.

DRUG

Ivabradine Placebo + Coordinated Care

The control (placebo) oral tablets will be similar to the study drug, ivabradine. The control packaging matches the packaging. Participants will receive Ivabradine placebo for a duration of 3 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with ivabradine placebo administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, feedback, nutrition counseling, motivation, education, and assisted care through care coordinator.

DRUG

IVIG + Usual Care

Participants will receive IVIG for a duration of 9 months and usual non-pharmacologic care (control) for a duration of 3 months. This will be concurrent with scheduled IVIG administration.

DRUG

IVIG Placebo + Usual Care

Normal saline given intravenously will be the control (placebo) product. The normal saline will be of similar formulation and appearance to IVIG. Participants will receive IVIG placebo for a duration of 9 months and usual non-pharmacologic care (control) for a duration of 3 months. This will be concurrent with scheduled IVIG placebo administration.

DRUG

Ivabradine + Usual Care

Participants will receive Ivabradine for a duration of 3 months and usual non-pharmacologic care (control) for a duration of 3 months, concurrent with ivabradine administration.

DRUG

Ivabradine Placebo + Usual Care

The control (placebo) oral tablets will be similar to the study drug, ivabradine. The control packaging matches the packaging. Participants will receive Ivabradine placebo for a duration of 3 months and usual non-pharmacologic care (control) for a duration of 3 months, concurrent with ivabradine placebo administration.

Locations (50)

East Alabama Medical Center - Appendix B Only

Opelika, Alabama, United States

Center for Complex Neurology - Appendix A & B

Phoenix, Arizona, United States

University of Arkansas for Medical Sciences - Appendix A & B

Little Rock, Arkansas, United States

University of California San Diego - Appendix B Only

La Jolla, California, United States

Cedars Sinai Medical Center - Appendix A & B

Los Angeles, California, United States

Stanford University - Appendix B Only

Stanford, California, United States

University of Colorado Anschutz Medical Campus Clinical and Translational Research Center (CTRC) - Appendix A & B

Aurora, Colorado, United States

MedStar National Rehabilitation Hospital - Appendix B only

Washington D.C., District of Columbia, United States

University of Florida Health - Appendix A & B

Gainesville, Florida, United States

Lakeland Regional Medical Center - Appendix A & B

Lakeland, Florida, United States

Innovation Clinical Trials Inc.- Appendix A & B

Palmetto Bay, Florida, United States

Grady Memorial Hospital - Woodruff Memorial Research - Appendix A & B

Atlanta, Georgia, United States

Morehouse School of Medicine - Appendix A & B

Atlanta, Georgia, United States

Queens Medical Center - Appendix B Only

Honolulu, Hawaii, United States

Rush University Medical Center - Appendix B Only

Chicago, Illinois, United States

University of Illinois at Chicago - Appendix A & B

Chicago, Illinois, United States

NorthShore University HealthSystem - Evanston Hospital - Appendix B Only

Evanston, Illinois, United States

University of Iowa - Appendix A & B

Iowa City, Iowa, United States

University of Kansas Medical Center CTSU Fairway - Appendix A & B

Fairway, Kansas, United States

University of Kentucky Medical Center - Appendix A & B

Lexington, Kentucky, United States

University Medical Center New Orleans - Appendix A & B

New Orleans, Louisiana, United States

Johns Hopkins Hospital - Appendix A Only

Baltimore, Maryland, United States

Brigham and Women's Hospital - Appendix A Only

Boston, Massachusetts, United States

Henry Ford Hospital - Appendix A & B

Detroit, Michigan, United States

Mayo Clinic - Appendix A & B

Rochester, Minnesota, United States

University of Mississippi Medical Center - Appendix A & B

Jackson, Mississippi, United States

Washington University School of Medicine - Appendix B Only

St Louis, Missouri, United States

University at Buffalo - Appendix A & B

Buffalo, New York, United States

St. Lawrence Health Medical Campus - Appendix A & B

Canton, New York, United States

Columbia University Irving Medical Center - Appendix A & B

New York, New York, United States

Stony Brook University Hospital - Appendix A & B

Stony Brook, New York, United States

Montefiore Medical Center - Moses Campus - Appendix B

The Bronx, New York, United States

Duke University Hospital - Appendix A & B

Durham, North Carolina, United States

East Carolina University - Appendix B Only

Greenville, North Carolina, United States

Cleveland Clinic - Appendix A & B

Cleveland, Ohio, United States

University of Oklahoma Health Science Center - Oklahoma Clinical and Translational Science Institute - Appendix A & B

Oklahoma City, Oklahoma, United States

Oregon Health and Science University - Appendix A & B

Portland, Oregon, United States

Kent Hospital - Appendix A & B

Pawtucket, Rhode Island, United States

Vanderbilt University Medical Center

Nashville, Tennessee, United States

National Neuromuscular Research Institute - Appendix A & B

Austin, Texas, United States

Southwest Family Medicine Associates - Appendix A & B

Dallas, Texas, United States

University of Texas Health Science Center at Houston

Houston, Texas, United States

University of Texas Health Science Center at San Antonio - Appendix A & B

San Antonio, Texas, United States

Bateman Horne Center - Appendix B Only

Salt Lake City, Utah, United States

Vermont Lung Center, University of Vermont - Appendix B Only

Burlington, Vermont, United States

University of Virginia Health System, University Hospital - Appendix A & B

Charlottesville, Virginia, United States

Sentara Norfolk General Hospital - Appendix A & B

Norfolk, Virginia, United States

Evergreen Hospital Medical Center - Appendix A & B

Kirkland, Washington, United States

Providence Medical Research Center - Appendix A & B

Spokane, Washington, United States

Marshall Health - University Physicians and Surgeons - Appendix A & B

Huntington, West Virginia, United States